CDMO Rentschler Biopharma is moving out of the cell and gene therapy space and putting more of its chips behind biologics. The strategic shift means that the company will end operations at its Stevenage, U.K., site, which is devoted to cell and gene therapies. The cell and gene therapy market has experienced “slower-than-expected growth” and demand hasn’t met Rentschler’s expectations, CEO Benedikt von Braunmühl explained in a company press release. Source: Fierce Pharma 30/2/2025